These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6980365)

  • 1. Stable plasma protein solution. Modern preparation methods reduce risk of untoward reactions.
    Schiff P
    Med J Aust; 1982 Jun; 1(12):493. PubMed ID: 6980365
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro assay for prekallikrein activator (PKA).
    Lundblad JL
    Dev Biol Stand; 1979; 44():107-14. PubMed ID: 317466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a bradykinin-generating hypotensive substance in plasma protein fraction: prekallikrein activator (PKA-beta-Xiia).
    Bakker JC; de Vries-van Rossen A; Radema H; Bleeker W; Ufkes JG; van Rosevelt RF; van Mourik JA
    Adv Exp Med Biol; 1983; 156 (Pt B)():1091-7. PubMed ID: 6602466
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypotensive effect of prekallikrein activator (PKA) in plasma protein fraction (PPF).
    Heinonen J; Peltola K; Himberg JJ; Suomela H
    Dev Biol Stand; 1980; 48():129-30. PubMed ID: 7024018
    [No Abstract]   [Full Text] [Related]  

  • 5. Bradykinin-mediated hypotension after infusion of plasma-protein fraction.
    Van Rosevelt RF; Bakker JC; Sinclair DM; Damen J; Van Mourik JA
    J Lab Clin Med; 1982 Aug; 100(2):288-95. PubMed ID: 6980251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prekallikrein activator in human albumin.
    Paton CJ; Kerry PJ
    Lancet; 1981 Oct; 2(8249):747. PubMed ID: 6116876
    [No Abstract]   [Full Text] [Related]  

  • 7. Prekallikrein activator levels and side effects with human albumin preparations.
    Lüben G; Quast U; Geiger H
    Dev Biol Stand; 1980; 48():123-7. PubMed ID: 6974110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKA contamination of immunoglobulin G.
    Eibl MM
    N Engl J Med; 1985 Aug; 313(9):581. PubMed ID: 3875038
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct assay of factor XIIa in plasma with synthetic chromogenic substrates.
    Kluft C; Svendsen L; Los P
    Adv Exp Med Biol; 1983; 156():201-4. PubMed ID: 6190367
    [No Abstract]   [Full Text] [Related]  

  • 10. Contact activation patterns of human plasma measured with a fluorogenic substrate.
    Dooijewaard G; Kluft C
    Adv Exp Med Biol; 1983; 156():115-20. PubMed ID: 6602460
    [No Abstract]   [Full Text] [Related]  

  • 11. Standardization of prekallikrein activator (PKA): the 1st British reference preparation for PKA.
    Kerry PJ; Curtis AD; Paton CJ; Thomas DP
    Br J Haematol; 1982 Oct; 52(2):275-81. PubMed ID: 6982063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma protein fraction. Product improvement studies.
    Ng PK; Fournel MA; Lundblad JL
    Transfusion; 1981; 21(6):682-5. PubMed ID: 6976030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temperature sensitivity within the pasteurization temperature range of prekallikrein activator in stable plasma protein solution (SPPS).
    Marley PB; Gilbo CM
    Transfusion; 1981; 21(3):320-4. PubMed ID: 6972108
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: a clinical study in patients having open-heart surgery.
    Heinonen J; Peltola K; Himberg JJ; Suomela H
    Ann Thorac Surg; 1982 Mar; 33(3):244-9. PubMed ID: 6978689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of beta-FXIIa in plasma of volunteers and polytraumatized patients.
    Fuhrer G; Gallimore MJ; Heller W; Hoffmeister HE
    Prog Clin Biol Res; 1987; 236B():77-84. PubMed ID: 3497407
    [No Abstract]   [Full Text] [Related]  

  • 16. Activated factor XII levels are dependent on factor XII 46C/T genotypes and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects.
    Ishii K; Oguchi S; Murata M; Mitsuyoshi Y; Takeshita E; Ito D; Tanahashi N; Fukuuchi Y; Oosumi K; Matsumoto K; Kitajima M; Yamamoto M; Watanabe G; Ikeda Y; Watanabe K
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):277-84. PubMed ID: 10870808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prekallikrein activator.
    Gallimore MJ; Friberger P
    Thromb Haemost; 1984 Dec; 52(3):366. PubMed ID: 6335791
    [No Abstract]   [Full Text] [Related]  

  • 18. [Study and clinical significance of the fibrinolysis component dependent on factor XIIa].
    Arkhipov AG; Eremin GF
    Lab Delo; 1985; (11):648-51. PubMed ID: 2417013
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of Hageman factor by proteases released during antigen challenge of human lung.
    Newball HH; Meier HL; Kaplan AP; Revak SD; Cochrane CG; Lichtenstein LM
    Trans Assoc Am Physicians; 1981; 94():126-33. PubMed ID: 7046190
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical use of a human albuminoid preparation (SPPS) produced by the continuous small volume mixing (CSVM) fractionation technique.
    Cash JD
    Dev Biol Stand; 1980; 48():43-8. PubMed ID: 7274563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.